image
Healthcare - Medical - Devices - NYSE - US
$ 70.75
2.79 %
$ 11.3 B
Market Cap
94.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one GMED stock under the worst case scenario is HIDDEN Compared to the current market price of 70.8 USD, Globus Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one GMED stock under the base case scenario is HIDDEN Compared to the current market price of 70.8 USD, Globus Medical, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one GMED stock under the best case scenario is HIDDEN Compared to the current market price of 70.8 USD, Globus Medical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GMED

image
$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.52 B REVENUE
60.62%
166 M OPERATING INCOME
24.67%
103 M NET INCOME
-16.19%
521 M OPERATING CASH FLOW
113.82%
-176 M INVESTING CASH FLOW
-58.11%
-27.7 M FINANCING CASH FLOW
88.05%
657 M REVENUE
5.05%
60.3 M OPERATING INCOME
25.32%
26.5 M NET INCOME
-48.87%
210 M OPERATING CASH FLOW
3.28%
-104 M INVESTING CASH FLOW
-595.68%
59.7 M FINANCING CASH FLOW
205.02%
Balance Sheet Globus Medical, Inc.
image
Current Assets 2.18 B
Cash & Short-Term Investments 890 M
Receivables 558 M
Other Current Assets 730 M
Non-Current Assets 3.07 B
Long-Term Investments 0
PP&E 612 M
Other Non-Current Assets 2.46 B
16.95 %10.62 %13.89 %11.64 %46.90 %Total Assets$5.3b
Current Liabilities 856 M
Accounts Payable 75.1 M
Short-Term Debt 20.5 M
Other Current Liabilities 760 M
Non-Current Liabilities 551 M
Long-Term Debt 527 M
Other Non-Current Liabilities 23.9 M
5.34 %54.05 %37.46 %Total Liabilities$1.4b
EFFICIENCY
Earnings Waterfall Globus Medical, Inc.
image
Revenue 2.52 B
Cost Of Revenue 1.04 B
Gross Profit 1.48 B
Operating Expenses 1.32 B
Operating Income 166 M
Other Expenses 63 M
Net Income 103 M
3b3b3b3b2b2b2b2b1b1b500m500m003b(1b)1b(1b)166m(63m)103mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
58.90% GROSS MARGIN
58.90%
6.59% OPERATING MARGIN
6.59%
4.09% NET MARGIN
4.09%
2.47% ROE
2.47%
1.96% ROA
1.96%
3.21% ROIC
3.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Globus Medical, Inc.
image
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 103 M
Depreciation & Amortization 254 M
Capital Expenditures -115 M
Stock-Based Compensation 54.2 M
Change in Working Capital 0
Others 235 M
Free Cash Flow 405 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Globus Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for GMED of $79.7 , with forecasts ranging from a low of $71 to a high of $100 .
GMED Lowest Price Target Wall Street Target
71 USD 0.35%
GMED Average Price Target Wall Street Target
79.7 USD 12.60%
GMED Highest Price Target Wall Street Target
100 USD 41.34%
Price
Max Price Target
Min Price Target
Average Price Target
100100909080807070606050504040May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Globus Medical, Inc.
image
Sold
0-3 MONTHS
590 K USD 1
3-6 MONTHS
26.7 M USD 5
6-9 MONTHS
2.89 M USD 3
9-12 MONTHS
5.39 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
GMED Stock May Benefit Following the Acquisition of Nevro Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market. zacks.com - 6 days ago
Globus Medical completes acquisition of Nevro Corp. AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. globenewswire.com - 1 week ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w. businesswire.com - 3 weeks ago
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally? Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains. zacks.com - 3 weeks ago
Should You Hold Globus Medical Stock in Your Portfolio Now? GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects. zacks.com - 3 weeks ago
New Product Launches Benefit GMED Stock Amid Macro Issues Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025. zacks.com - 3 weeks ago
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades. zacks.com - 1 month ago
Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, and Modulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system. globenewswire.com - 1 month ago
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025. globenewswire.com - 1 month ago
Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. globenewswire.com - 1 month ago
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock? Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately. zacks.com - 1 month ago
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. prnewswire.com - 1 month ago
8. Profile Summary

Globus Medical, Inc. GMED

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 11.3 B
Dividend Yield 0.00%
Description Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Contact 2560 General Armistead Avenue, Audubon, PA, 19403 https://www.globusmedical.com
IPO Date Aug. 3, 2012
Employees 5300
Officers Mr. David C. Paul Co-Founder & Executive Chairman Mr. Daniel T. Scavilla President, Chief Executive Officer & Director Mr. Brian J. Kearns Senior Vice President of Business Development & Investor Relations Mr. Keith W. Pfeil Chief Financial Officer & Chief Operating Officer Ms. Kelly G. Huller Esq. Executive Vice President, General Counsel & Corporate Secretary